Breaking News
FONT-SIZE Plus   Neg
Share SHARE

GlaxoSmithKline Announces Regulatory Submission To FDA For Albiglutide

RELATED NEWS
Trade GSK now with 

GlaxoSmithKline plc (GSK: Quote, GSK.L) announced a regulatory submission to the US FDA for albiglutide, an investigational once-weekly treatment for adult patients with type 2 diabetes. GlaxoSmithKline intends to submit a regulatory application in the European Union in early 2013.

Albiglutide, a GLP-1 receptor agonist, is an investigational biological product for the treatment of type 2 diabetes designed for once-weekly subcutaneous dosing. Albiglutide is not yet approved as a treatment for type 2 diabetes or any other indication anywhere in the world.

Click here to receive FREE breaking news email alerts for GlaxoSmithKline PLC and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
With a firming job market helping to unleash pent-up demand for new homes, the National Association of Home Builders released a report on Wednesday showing that U.S. homebuilder confidence jumped to its highest level in almost nine years in September. Stocks have moved modestly higher in early trading on Wednesday, extending the upward move seen in the previous session. The major averages have all moved to the upside, with the Dow reaching a new record intraday high. With a substantial decrease in energy prices more than offsetting higher prices for food and shelter, the Labor Department released a report on Wednesday showing an unexpected drop in U.S. consumer prices in the month of August.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.